FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2296554413> ?p ?o ?g. }

• W2296554413 abstract "Group IVA cytosolic phospholipase A2 (cPLA2α) plays an important role in tumorigenesis and angiogenesis. It is overexpressed in basal-like breast cancer (BLBC), which is aggressive and usually triple-negative, making it unresponsive to current targeted therapies. Here, we evaluated the anti-angiogenic effects of a specific cPLA2α inhibitor, AVX235, in a patient-derived triple-negative BLBC model. Mice bearing orthotopic xenografts received i.p. injections of AVX235 or DMSO vehicle daily for 1 week and then every other day for up to 19 days. Six treated and six control mice were terminated after 2 days of treatment, and the tumors excised for high resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS) and prostaglandin E2 (PGE2) enzyme immunoassay (EIA) analysis. A 1-week imaging study was performed on a separate cohort of mice. Longitudinal dynamic contrast enhanced (DCE)-MRI was performed before, after 4 days, and after 1 week of treatment. The mice were then perfused with a radiopaque vascular casting agent, and the tumors excised for micro-CT angiography. Subsequently, tumors were sectioned and stained with lectin and for Ki67 or α-smooth muscle actin to quantify endothelial cell proliferation and vessel maturity, respectively. Partial least squares discriminant analysis was performed on the multivariate HR MAS MRS data, and non-parametric univariate analyses using Mann–Whitney U tests (α = 0.05) were performed on all other data. Glycerophosphocholine and PGE2 levels, measured by HR MAS MRS and EIA, respectively, were lower in treated tumors after 2 days of treatment. These molecular changes are expected downstream effects of cPLA2α inhibition and were followed by significant tumor growth inhibition after 8 days of treatment. DCE-MRI revealed that AVX235 treatment caused a decrease in tumor perfusion. Concordantly, micro-CT angiography showed that vessel volume fraction, density, and caliber were reduced in treated tumors. Moreover, histology showed decreased endothelial cell proliferation and fewer immature vessels in treated tumors. These results demonstrate that cPLA2α inhibition with AVX235 resulted in decreased vascularization and perfusion and subsequent inhibition of tumor growth. Thus, cPLA2α inhibition may be a potential new therapeutic option for triple-negative basal-like breast cancer." @default.
• W2296554413 created "2016-06-24" @default.
• W2296554413 creator A5002516417 @default.
• W2296554413 creator A5015146814 @default.
• W2296554413 creator A5031687005 @default.
• W2296554413 creator A5032140391 @default.
• W2296554413 creator A5033013696 @default.
• W2296554413 creator A5037330214 @default.
• W2296554413 creator A5037739123 @default.
• W2296554413 creator A5053950619 @default.
• W2296554413 creator A5058230776 @default.
• W2296554413 creator A5064756368 @default.
• W2296554413 date "2016-03-07" @default.
• W2296554413 modified "2023-10-16" @default.
• W2296554413 title "Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model" @default.
• W2296554413 cites W1487603533 @default.
• W2296554413 cites W1920973919 @default.
• W2296554413 cites W1965804989 @default.
• W2296554413 cites W1970050679 @default.
• W2296554413 cites W1970989453 @default.
• W2296554413 cites W1977887541 @default.
• W2296554413 cites W1978293462 @default.
• W2296554413 cites W1980320450 @default.
• W2296554413 cites W1992483596 @default.
• W2296554413 cites W1993866602 @default.
• W2296554413 cites W2025342576 @default.
• W2296554413 cites W2026889617 @default.
• W2296554413 cites W2031321898 @default.
• W2296554413 cites W2032995169 @default.
• W2296554413 cites W2035077913 @default.
• W2296554413 cites W2061633610 @default.
• W2296554413 cites W2062215309 @default.
• W2296554413 cites W2066600235 @default.
• W2296554413 cites W2071744304 @default.
• W2296554413 cites W2072000048 @default.
• W2296554413 cites W2073241645 @default.
• W2296554413 cites W2073290778 @default.
• W2296554413 cites W2091006673 @default.
• W2296554413 cites W2098722265 @default.
• W2296554413 cites W2099335989 @default.
• W2296554413 cites W2104300873 @default.
• W2296554413 cites W2108560895 @default.
• W2296554413 cites W2120369670 @default.
• W2296554413 cites W2127133796 @default.
• W2296554413 cites W2128503288 @default.
• W2296554413 cites W2131994307 @default.
• W2296554413 cites W2132416992 @default.
• W2296554413 cites W2138766928 @default.
• W2296554413 cites W2144343828 @default.
• W2296554413 cites W2152064969 @default.
• W2296554413 cites W2156701124 @default.
• W2296554413 cites W2162542545 @default.
• W2296554413 cites W2163112792 @default.
• W2296554413 cites W2167279371 @default.
• W2296554413 cites W2169150770 @default.
• W2296554413 doi "https://doi.org/10.1186/s12885-016-2225-1" @default.
• W2296554413 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4782288" @default.
• W2296554413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26951085" @default.
• W2296554413 hasPublicationYear "2016" @default.
• W2296554413 type Work @default.
• W2296554413 sameAs 2296554413 @default.
• W2296554413 citedByCount "30" @default.
• W2296554413 countsByYear W22965544132016 @default.
• W2296554413 countsByYear W22965544132017 @default.
• W2296554413 countsByYear W22965544132018 @default.
• W2296554413 countsByYear W22965544132019 @default.
• W2296554413 countsByYear W22965544132021 @default.
• W2296554413 countsByYear W22965544132022 @default.
• W2296554413 countsByYear W22965544132023 @default.
• W2296554413 crossrefType "journal-article" @default.
• W2296554413 hasAuthorship W2296554413A5002516417 @default.
• W2296554413 hasAuthorship W2296554413A5015146814 @default.
• W2296554413 hasAuthorship W2296554413A5031687005 @default.
• W2296554413 hasAuthorship W2296554413A5032140391 @default.
• W2296554413 hasAuthorship W2296554413A5033013696 @default.
• W2296554413 hasAuthorship W2296554413A5037330214 @default.
• W2296554413 hasAuthorship W2296554413A5037739123 @default.
• W2296554413 hasAuthorship W2296554413A5053950619 @default.
• W2296554413 hasAuthorship W2296554413A5058230776 @default.
• W2296554413 hasAuthorship W2296554413A5064756368 @default.
• W2296554413 hasBestOaLocation W22965544131 @default.
• W2296554413 hasConcept C121608353 @default.
• W2296554413 hasConcept C126322002 @default.
• W2296554413 hasConcept C142724271 @default.
• W2296554413 hasConcept C173633252 @default.
• W2296554413 hasConcept C181199279 @default.
• W2296554413 hasConcept C2780394083 @default.
• W2296554413 hasConcept C530470458 @default.
• W2296554413 hasConcept C55493867 @default.
• W2296554413 hasConcept C71924100 @default.
• W2296554413 hasConcept C86803240 @default.
• W2296554413 hasConceptScore W2296554413C121608353 @default.
• W2296554413 hasConceptScore W2296554413C126322002 @default.
• W2296554413 hasConceptScore W2296554413C142724271 @default.
• W2296554413 hasConceptScore W2296554413C173633252 @default.
• W2296554413 hasConceptScore W2296554413C181199279 @default.
• W2296554413 hasConceptScore W2296554413C2780394083 @default.
• W2296554413 hasConceptScore W2296554413C530470458 @default.
• W2296554413 hasConceptScore W2296554413C55493867 @default.
• W2296554413 hasConceptScore W2296554413C71924100 @default.

• next